生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

未开盘 05-15 16:00:00 EDT

1,103.63

-23.23

-2.06%

最高1,130.49	最低1,101.25	成交量11.72亿
今开1,127.74	昨收1,126.86	日振幅2.60%
总市值0.00	流通市值0.00	总股本0.00
成交额157.83亿	换手率--	流通股本0.00
市净率6.806433	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1103.6333,"timestamp":1778875199999,"preClose":1126.8594,"halted":0,"volume":1172020739,"delay":0,"changeRate":-0.020611,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-23.226074,"latestTime":"05-15 16:00:00 EDT","open":1127.7427,"high":1130.492,"low":1101.2454,"amount":15782671570.549343,"amplitude":0.025954,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.806433,"peRate":-148.18989,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139/tweets","defaultTab":"tweets","newsList":[{"id":"2636092234","title":"保诚(02378)拟收购BHARTI LIFE INSURANCE 控股权以调整印度业务部署","url":"https://stock-news.laohu8.com/highlight/detail?id=2636092234","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636092234?lang=zh_cn&edition=full","pubTime":"2026-05-17 20:05","pubTimestamp":1779019529,"startTime":"0","endTime":"0","summary":"智通财经APP讯，保诚 发布公告，2026年5月17日，为推进其印度业务的策略性部署，已同意向Bharti Life Ventures Pvt Ltd及360 ONE Asset Management收购印度知名人寿保险公司 Bharti Life Insurance Company Limited的75%股权。该业务预计将发挥保诚与 Bharti 的品牌优势，并透过保诚的营运实力加以强化。保诚亦期待与Bharti Enterprises旗下其他业务及相关实体紧密合作。该项交易的监管审批预计将要求保诚减持其于ICICIPru Life的股权至10%以下。待获得相关批准后，健康保险业务预计将于2026年内开始营运。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4173","BK4563","LU0251144936.SGD","BK4139","MNDmain","LU1880383366.USD","LU0575583348.USD","LU0211331839.USD","LIFE","02378","LU0048597586.USD","LU1015430645.USD","BK1184"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159036048","title":"ImmunityBio与日本BCG实验室达成独家美国协议，引进东京菌株以增强国内供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1159036048","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159036048?lang=zh_cn&edition=full","pubTime":"2026-05-17 01:36","pubTimestamp":1778952993,"startTime":"0","endTime":"0","summary":"ImmunityBio已与日本BCG实验室签署了一项独家美国协议，旨在引进东京菌株的BCG（卡介苗）。这一合作将显著增强美国境内的BCG供应稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149676722","title":"再生元制药关键试验未达主要终点：无进展生存期改善未具统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1149676722","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149676722?lang=zh_cn&edition=full","pubTime":"2026-05-16 08:23","pubTimestamp":1778890989,"startTime":"0","endTime":"0","summary":"再生元制药公司一项临床试验的主要终点——无进展生存期的改善——未能达到统计学显著性标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU0823434740.USD","LU0882574055.USD","LU0823434583.USD","LU2362541513.USD","LU0889565916.HKD","LU2106854487.HKD","LU2362540622.SGD","LU0109394709.USD","BK4139","LU0114720955.EUR","LU1917777945.USD","LU0053666078.USD","LU0289739699.SGD","LU0320765992.SGD","LU1974910355.USD","BK4585","LU0058720904.USD","LU2089984988.USD","LU2237438978.USD","REGN","BK4588","LU0823416689.USD","LU2468319806.SGD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122731183","title":"再生元制药公布一线治疗不可切除或转移性黑色素瘤的Fianlimab（Lag-3抑制剂）联合疗法三期试验最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1122731183","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122731183?lang=zh_cn&edition=full","pubTime":"2026-05-16 08:20","pubTimestamp":1778890817,"startTime":"0","endTime":"0","summary":"再生元制药公司（Regeneron Pharmaceuticals）就其研发的Fianlimab（一种Lag-3抑制剂）联合疗法，在一线治疗不可切除或转移性黑色素瘤患者中的三期临床试验提供了最新动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2362540622.SGD","LU0823434740.USD","LU0109394709.USD","LU2089984988.USD","LU2362541513.USD","BK4139","LU0882574055.USD","LU1917777945.USD","LU2468319806.SGD","BK4588","LU0823434583.USD","LU0289739699.SGD","BK4585","LU0114720955.EUR","LU0053666078.USD","LU0058720904.USD","LU0320765992.SGD","LU2023250504.SGD","REGN","LU1974910355.USD","LU2106854487.HKD","LU0823416689.USD","LU2237438978.USD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182453328","title":"Enlivex收到纳斯达克最低买入价通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1182453328","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182453328?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:54","pubTimestamp":1778878475,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd.近日宣布，已收到纳斯达克股票市场发出的关于其普通股买入价不符合持续上市标准的通知。该通知指出，在连续30个交易日内，公司股票的收盘买入价低于每股1.00美元的最低要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120460888","title":"Allarity Therapeutics公布2026年第一季度业绩并持续推进Stenoparib在多癌种中的开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1120460888","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120460888?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:31","pubTimestamp":1778877074,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc公布了其2026年第一季度的财务与业务进展。报告期内，公司核心工作聚焦于其候选药物Stenoparib在多种癌症类型中的持续开发。公司正积极推动该药物的临床研究项目，旨在评估其在治疗不同恶性肿瘤方面的潜力与疗效。这一战略举措体现了Allarity Therapeutics致力于通过创新疗法满足未竟医疗需求的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197521520","title":"Outlook Therapeutics完成FDA争议解决会议，Ons-5010最终裁决预计2026年5月揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1197521520","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197521520?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:06","pubTimestamp":1778875582,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已成功完成针对其候选药物Ons-5010的美国食品药品监督管理局（FDA）争议解决会议。公司正积极推动该药物的审批进程，最终监管决定预计将于2026年5月公布。这一关键步骤标志着Ons-5010在寻求上市批准的道路上取得了重要进展，为后续的潜在商业化铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198482140","title":"Candel Therapeutics 公布局部前列腺癌药物 Aglatimagene Besadenovec (Can-2409) 三期试验长期随访数据，显示多临床终点持续获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1198482140","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198482140?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:06","pubTimestamp":1778875578,"startTime":"0","endTime":"0","summary":"在2026年美国泌尿外科协会年会上，Candel Therapeutics 公布了其针对局部前列腺癌的候选药物 Aglatimagene Besadenovec (Can-2409) 三期临床试验的长期随访数据。数据显示，经过延长随访期，该疗法在多个关键临床终点上持续为患者带来显著的临床获益。\n此次公布的数据进一步证实了 Can-2409 在治疗局部前列腺癌患者中的持久疗效与安全性。长期跟踪结果凸显了该疗法在延缓疾病进展、改善患者生活质量等核心指标上的积极作用，为这一创新疗法的潜在价值提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194394923","title":"Outlook Therapeutics公布2026财年第二季度财务业绩并发布公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1194394923","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194394923?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:06","pubTimestamp":1778875575,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已正式发布其2026财年第二季度的财务报告，同时向市场提供了公司业务进展的最新情况。此次披露涵盖了公司在该财季内的关键财务数据与运营更新，旨在让投资者全面了解公司当前的发展状况与未来规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154454876","title":"英国MHRA批准Beremagene Geperpavec（Vyjuvek）用于治疗营养不良型大疱性表皮松解症","url":"https://stock-news.laohu8.com/highlight/detail?id=1154454876","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154454876?lang=zh_cn&edition=full","pubTime":"2026-05-16 02:12","pubTimestamp":1778868734,"startTime":"0","endTime":"0","summary":"英国药品和健康产品管理局（MHRA）已正式批准基因疗法Beremagene Geperpavec（商品名Vyjuvek）用于治疗营养不良型大疱性表皮松解症。这一决定为患有此种罕见且严重遗传性皮肤病的患者提供了一种新的治疗选择。\n该疗法由Krystal Biotech Inc.研发，旨在通过局部应用纠正导致皮肤脆弱和水疱形成的基因缺陷。此次批准标志着英国在推进创新基因疗法以应对未满足的医疗需求方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153076980","title":"FDA批准阿替利珠单抗用于部分患者肌层浸润性膀胱癌的辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1153076980","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153076980?lang=zh_cn&edition=full","pubTime":"2026-05-16 00:58","pubTimestamp":1778864321,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局(FDA)已批准阿替利珠单抗用于存在分子残留病灶的肌层浸润性膀胱癌患者的辅助治疗。\n同时，FDA亦批准将Natera公司的Signatera CDX作为泰圣奇膀胱癌治疗的伴随诊断工具，适用于部分患者。\n（注：文中提及的公司代码为ROPC.S）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU0345770308.USD","LU1988902786.USD","LU2264538146.SGD","LU0345770993.USD","LU0106261612.USD","LU0963586101.USD","LU2065171311.SGD","LU2065169927.USD","LU2324357040.USD","LU2065171402.SGD","LU2065731478.USD","NTRA","LU2065170008.USD","BK4139","LU0053671581.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035245","title":"Indaptus Therapeutics Q1净亏损收窄，现金储备大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035245","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635035245?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:46","pubTimestamp":1778859960,"startTime":"0","endTime":"0","summary":"　　Indaptus Therapeutics公布2026年第一季度财报。公司报告期内净亏损为254万美元，合每股亏损0.23美元，较上年同期的453万美元亏损和每股亏损9.11美元显著收窄。每股亏损的大幅减少主要源于2025年6月实施的1比28反向股票分割带来的股份数量增加。一般及行政费用为167万美元，同比略有下降。　　截至季末，公司现金及现金等价物仅为150万美元，较2025年末的850万美元大幅下降。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6357238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035758","title":"Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035758","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635035758?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:41","pubTimestamp":1778859660,"startTime":"0","endTime":"0","summary":"　　Atrium Therapeutics公布2026年第一季度财报。公司报告期内净亏损为1663万美元，合每股亏损0.97美元。作为对比，公司在作为Avidity Biosciences子公司期间的2025年同期净亏损为745万美元，合每股亏损0.44美元。需要说明的是，由于Atrium于2026年2月27日才完成从Avidity的分拆独立上市，本期财务数据不宜直接与历史同期进行比较。　　Atrium于2月27日正式作为独立公司登陆纳斯达克。ATR 1072的IND申请预计于2026年下半年提交，ATR 1086的IND申请预计于2027年提交。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6355365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE0009354923.USD","BK4539","BK4505","BK4588","BK4139","BK4585","LENZ","BMS","BK4007","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635033220","title":"再鼎医药(ZLAB)逆市上涨1.52% zoci近日获美国FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2635033220","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635033220?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:40","pubTimestamp":1778856000,"startTime":"0","endTime":"0","summary":"金吾财讯 |再鼎医药 逆市上涨1.52%，最新报20.64美元，成交额774.69万美元。消息面上，再鼎医药官微日前宣布，美国食品药品监督管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。此外，高盛新近披露，已于5月8日以每股均价15.09港元场外增持再鼎医药545.57万股H股股份，价值约8,232.65万港元。增持后，高盛最新持股数目为7,070.61万股股份，好仓比例由5.75%升至6.23%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NWIzNTQyNTc0Mjc1MDI=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWIzNTQyNTc0Mjc1MDI=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300518","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB","BK1588","LU2488822045.USD","BK4526","BK4588","BK1161","09688","BK4548","BK4139","BK4585","BK4531","BK1574","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138036084","title":"阿布扎比主权基金大幅减持西维斯健康股份，持股量骤降逾六成","url":"https://stock-news.laohu8.com/highlight/detail?id=1138036084","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138036084?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:30","pubTimestamp":1778855441,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件披露，阿布扎比主权财富基金穆巴达拉投资公司已大幅削减了其在西维斯健康的持股。此次减持幅度高达63.4%，使其持有的股份数量降至54,800股。\n这一变动标志着该主权基金对这家美国医疗保健巨头投资策略的显著调整。文件显示，经过此次操作，穆巴达拉投资公司对西维斯健康的持股比例已大幅降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRY28.SGD","LU0795875169.SGD","LU1823568750.SGD","LU1989771016.USD","LU2250418816.HKD","LU1366333091.USD","IE00BFSS7M15.SGD","LU0096362180.USD","LU2089984988.USD","IE0002141913.USD","BK4533","LU1061106388.HKD","LU2129689514.USD","BK4147","LU1093756168.USD","LU2106854487.HKD","LU0456855351.SGD","LU1035773651.USD","IE0004445239.USD","LU0289739343.SGD","BK4139","LU0289739699.SGD","LU1992135399.USD","BK4543","IE00B4JS1V06.HKD","LU0029864427.USD","LU1093756325.SGD","SG9999001440.SGD","SG9999015952.SGD","LU1929549753.HKD","IE0004445015.USD","LU0069063385.USD","LU0211331839.USD","LU0719512351.SGD","IE000SO60NU8.SGD","LU0823416689.USD","LU0320765646.SGD","IE00BVYPNV92.GBP","LU0274383776.USD","LU1934455863.HKD","LU1989772840.SGD","LU2089283258.USD","LU2112291526.USD","LU2272731865.HKD","LU0957808578.USD","LU0859254822.USD","LU1815333072.USD","LU0689472784.USD","LU1974910355.USD","IE00B42XCP33.USD","LU2237443465.HKD","LU0965509283.SGD","LU1267930573.SGD","IE00BFTCPJ56.SGD","LU0114720955.EUR","IE00B4R5TH58.HKD","LU0097036916.USD","BK4551","LU0082616367.USD","LU0234570918.USD","LU2244417387.USD","LU0738911758.USD","IE00B2B36J28.USD","LU0310800379.SGD","LU2347655156.SGD","LU0444973449.USD","LU2360106780.USD","LU1852331112.SGD","BK4566","LU0251132253.USD","LU1003077747.HKD","IE00BGHQF631.EUR","LU0943347566.SGD","LU1551013342.USD","LU1992135472.HKD","LU0157215616.USD","LU1069347547.HKD","IE00BDGV0183.EUR","LU0417517546.SGD","LU0211327993.USD","LU2237443622.USD","LU1162221912.USD","LU0187121727.USD","LU0965509101.SGD","LU2129689605.HKD","LU2133065610.SGD","LU1585245621.USD","LU2931357623.SGD","LU1642822529.SGD","LU1670627923.USD","IE00BJJMRX11.SGD","LU0158827948.USD","IE0005OL40V9.USD","LU1923622614.USD","LU1430594728.SGD","SG9999015945.SGD","LU0823434583.USD","LU0203347892.USD","LU0348723411.USD","LU0868494617.USD","LU1699723380.USD","IE00B775H168.HKD","IE000F7OJYX1.SGD","LU2237443549.SGD","LU2237443978.SGD","LU0689626769.HKD","LU1670628061.USD","BK4196","IE0000B7K699.USD","LU1815336760.USD","IE00BN29S564.USD","LU1496350502.SGD","LU2357305700.SGD","SG9999015986.USD","LU0432979614.USD","LU0124676726.USD","LU0056508442.USD","LU0198837287.USD","LU2089985449.USD","LU0472753341.HKD","LU0820561818.USD","LRCX","LU1732800096.USD","LU2237443895.HKD","LU0256863902.USD","BK4581","LU1235294995.USD","BK4550","BK4559","LU1244550494.USD","LU0122379950.USD","LU0912757837.SGD","LU0320765489.SGD","LU0957791311.USD","LU1291159041.SGD","LU1983299246.USD","LU2357627491.SGD","LU2473716301.USD","LU0256863811.USD","LU0289961442.SGD","LU1732799900.SGD","LU0211328371.USD","LU0553294199.USD","LU1571399168.USD","LU0203345920.USD","IE00BQXX3D17.EUR","LU2242649171.HKD","LU0234572021.USD","LU1046421795.USD","BK4504","IE00B1BXHZ80.USD","BK4588","LU0661504455.SGD","LU2322448957.HKD","IE00B19Z3B42.SGD","LU0708994859.HKD","IE00B3PB1722.GBP","LU0170899867.USD","LU2322448791.USD","LU0058720904.USD","LU1037948897.HKD","LU0882574055.USD","IE00B5949003.HKD","IE00B7SZLL34.SGD","LU1917777945.USD","IE000BZT7R73.USD","LU0444971666.USD","LU2272731782.SGD","LU0861579265.USD","LU2089284900.SGD","LU0820561909.HKD","LU0061474960.USD","LU0310799852.SGD","LU2023250843.SGD","LU0048584097.USD","IE000MB6IJN5.SGD","LU1839511570.USD","LU1244550221.USD","LU0208291251.USD","LU1718418525.SGD","LU1934455194.USD","LU2129689431.USD","LU2433249047.HKD","IE0009355771.USD","LU0511384066.AUD","LU0965509010.AUD","IE00BJJMRZ35.SGD","LU0061475181.USD","LU0985320562.USD","LU0823434740.USD","IE00BQXX3F31.USD","LU2272731600.USD","LU1934455277.USD","IE00BLSP4452.SGD","LU0072461881.USD","LU1037948541.HKD","IE00BVYPNW00.USD","LU2125909593.SGD","SG9999011175.SGD","LU0949170772.SGD","LU1244550577.SGD","LU0081259029.USD","IE00BSNM7G36.USD","IE00BQXX3C00.GBP","IE00BKVL7J92.USD","IE000WAW04H5.SGD","LU0795875086.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU1074936037.SGD","IE00BFSS8Q28.SGD","LU0965508806.USD","BK4585","LU1023059063.AUD","LU1059921491.USD","CVS","IE00BLSP4239.USD","LU1551013425.SGD","LU1057294990.SGD","LU1989772923.USD","ABBV","IE00BBT3K403.USD","IE00B7KXQ091.USD","IE00BJT1NW94.SGD","LU0162691827.USD","LU0868494708.USD","LU1496350171.SGD","LU2237443382.USD","LRCU","SG9999003800.SGD","LU0098860793.USD","IE00BZ1G4Q59.USD","LU2087621335.USD","LU0006061336.USD","LU0057025933.USD","LU2468319806.SGD","BK4567","LU0545039389.USD","LU0128525929.USD","LU2125909247.SGD","BK4534","SG9999015978.USD","LU2023250504.SGD","IE0009356076.USD","IE00BN8TJ469.HKD","LU0070302665.USD","LU1548497426.USD","LU2023251221.USD","LU0476273544.USD","LU1720051017.SGD","LU0942090050.USD","LU1267930490.SGD","LU1720051108.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175918953","title":"Psyence Biomed宣布美国战略合作计划，聚焦GMP伊波加因研发与生产","url":"https://stock-news.laohu8.com/highlight/detail?id=1175918953","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175918953?lang=zh_cn&edition=full","pubTime":"2026-05-15 21:17","pubTimestamp":1778851034,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd宣布启动一项针对美国市场的战略合作计划，该计划的核心将集中于符合药品生产质量管理规范（GMP）标准的伊波加因（Ibogaine）研究及生产制造工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193910759","title":"Sana Biotechnology 通过市场发行计划出售约6900万美元股票","url":"https://stock-news.laohu8.com/highlight/detail?id=1193910759","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193910759?lang=zh_cn&edition=full","pubTime":"2026-05-15 21:01","pubTimestamp":1778850084,"startTime":"0","endTime":"0","summary":"Sana Biotechnology, Inc. 宣布，已通过其市场发行计划成功出售了价值约6900万美元的股票。该计划为公司提供了在公开市场上灵活筹集资金的有效途径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SANA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198980770","title":"康乃德生物医药控股有限公司 - 计划转售至多610万股普通股 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1198980770","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198980770?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:34","pubTimestamp":1778848459,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）提交的文件，康乃德生物医药控股有限公司（Connect Biopharma Holdings Ltd.）计划进行一项普通股转售。文件显示，此次拟议的转售涉及高达610万股公司普通股。\n这一行动通常意味着现有股东，例如早期投资者或公司内部人士，可能计划在公开市场上出售其持有的部分股份。此类转售备案是资本市场中的常规操作，旨在提前向市场披露潜在的股票供应增加，确保信息的透明性。投资者通常会关注此类动向，以评估其对公司股价可能产生的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191791145","title":"Moleculin 公布2026年第一季度财务业绩并通报关键性Miracle试验临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1191791145","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191791145?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:31","pubTimestamp":1778848276,"startTime":"0","endTime":"0","summary":"Moleculin Biotech, Inc. 已公布其2026年第一季度的财务业绩，并同步提供了关于其关键性Miracle试验的最新临床进展。\n公司报告了本季度的财务状况，同时详细阐述了其核心临床试验项目的当前状态与未来规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157177942","title":"Shah资本管理：坚信第二季度需回购1000万至2000万股诺瓦瓦克斯股票，以彰显对其科学与战略的信心并缓解历史稀释影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1157177942","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157177942?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:23","pubTimestamp":1778847798,"startTime":"0","endTime":"0","summary":"Shah资本管理公司强调，诺瓦瓦克斯医药（NVAX）必须在今年第二季度进行规模在1000万至2000万股之间的股票回购。此举被视为管理层对公司核心科学实力与长期发展战略投下坚定信心票的关键行动。同时，该回购计划旨在积极应对并缓解因过往融资活动所带来的股权稀释效应，从而向市场传递更为明确的积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4585","BK4139","BK4547","BK4568","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}